Chief, Interventional Cardiology
University of California San Francisco

Printed as of 12/18/2025

# **Disclosures**

### Personal Commercial (7)

Company Name	Relationship Category Compensation Level		Topic Area(s)	
Self				
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	Valvular Heart Disease	
Cardiovascular Research Foundation	Data Safety Monitoring Board	a Safety Monitoring Board Significant (>= \$5,000)		
Edwards Lifesciences	Consultant Fees/Honoraria Significant (>= \$5,000)		Valvular Heart Disease	
Edwards Lifesciences	Research/Research Grants	earch Grants Significant (>= \$5,000)		
Edwards Lifesciences	Research/Research Grants  ‡ Evaluation of the Identification and Management of Severe Aortic Stenosis within a Large Academic Health System		Valvular Heart Disease	
Medtronic	Research/Research Grants ‡ HALT Biomarker Study	Significant (>= \$5,000)	Valvular Heart Disease	
Prospect Health	Ownership Interest/Partnership/Principal	Modest (< \$5,000)	Other	

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

# Personal Organizational or Other Non-Commercial (0)

No disclosures on record

# Clinical Trial Enroller (5)

Trial Name	Trial Sponsor	Trial Funding Source
REPAIR MR	Abbott Laboratories	
PROGRESS Trial	Edwards Lifesciences	
CLASPIITR	Edwards Lifesciences	
TRISCEND II Trial	Edwards Lifesciences	
CLASPIIF	Edwards Lifesciences	

# Institutional Financial Decision-Making Role (0)

No disclosures on record

# **Expert Witness Testimony (1)**

Year	Case Title	Represented	Description	Compensation
Self				
2020	STEMI & aplastic anemia	Defendant † Ratcliffe Harten Galamaga LLP	Patient with aplastic anemia & STEMI and treated with DAPT/heparin prior to PCI c/b ICH.	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

# **Agreement**

**Certified Education Attestation** | Signed on 10/2/2025

URL for full agreement: http://disclosures. acc. org/Public/Definition/Certified Education Attestation Agreement agreeme

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/2/2025

Embargo | Signed on 10/2/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

### On-Going Obligation Agreement | Signed on 10/2/2025

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.